JP5705314B2 - アポトーシスシグナル調節キナーゼ阻害剤 - Google Patents

アポトーシスシグナル調節キナーゼ阻害剤 Download PDF

Info

Publication number
JP5705314B2
JP5705314B2 JP2013518740A JP2013518740A JP5705314B2 JP 5705314 B2 JP5705314 B2 JP 5705314B2 JP 2013518740 A JP2013518740 A JP 2013518740A JP 2013518740 A JP2013518740 A JP 2013518740A JP 5705314 B2 JP5705314 B2 JP 5705314B2
Authority
JP
Japan
Prior art keywords
cyclopropyl
triazol
carbon atoms
alkyl
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013518740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013530240A (ja
JP2013530240A5 (enExample
Inventor
ブリトン コーキー，
ブリトン コーキー，
グレゴリー ノット，
グレゴリー ノット，
ジェフ ザブロッキー，
ジェフ ザブロッキー，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド, ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2013530240A publication Critical patent/JP2013530240A/ja
Publication of JP2013530240A5 publication Critical patent/JP2013530240A5/ja
Application granted granted Critical
Publication of JP5705314B2 publication Critical patent/JP5705314B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013518740A 2010-07-02 2011-06-30 アポトーシスシグナル調節キナーゼ阻害剤 Active JP5705314B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36108010P 2010-07-02 2010-07-02
US61/361,080 2010-07-02
PCT/US2011/042694 WO2012003387A1 (en) 2010-07-02 2011-06-30 Apoptosis signal-regulating kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2013530240A JP2013530240A (ja) 2013-07-25
JP2013530240A5 JP2013530240A5 (enExample) 2014-06-19
JP5705314B2 true JP5705314B2 (ja) 2015-04-22

Family

ID=44318106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518740A Active JP5705314B2 (ja) 2010-07-02 2011-06-30 アポトーシスシグナル調節キナーゼ阻害剤

Country Status (17)

Country Link
US (3) US8440665B2 (enExample)
EP (1) EP2588475B1 (enExample)
JP (1) JP5705314B2 (enExample)
KR (1) KR101759759B1 (enExample)
CN (1) CN102985418B (enExample)
AU (1) AU2011272782B2 (enExample)
BR (1) BR112012033715A2 (enExample)
CA (1) CA2802743C (enExample)
EA (1) EA023040B1 (enExample)
ES (1) ES2543428T3 (enExample)
IL (2) IL223556A (enExample)
MX (1) MX2012015105A (enExample)
NZ (1) NZ604831A (enExample)
PL (1) PL2588475T3 (enExample)
PT (1) PT2588475E (enExample)
SI (1) SI2588475T1 (enExample)
WO (1) WO2012003387A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331095B1 (en) 2008-08-04 2014-10-15 CHDI Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
PH12012501480A1 (en) 2010-01-25 2012-10-22 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SI2588475T1 (sl) * 2010-07-02 2015-12-31 Gilead Sciences, Inc. Kinazni inhibitorji za regulacijo apoptoznega signala
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
JP5927201B2 (ja) 2010-12-16 2016-06-01 カルチャン リミテッド Ａｓｋ１阻害ピロロピリミジン誘導体
MX2014002459A (es) 2011-08-30 2014-04-10 Chdi Foundation Inc Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
US9981918B2 (en) 2011-08-30 2018-05-29 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2015201188B2 (en) * 2012-01-27 2016-12-15 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitor
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
HK1217117A1 (zh) 2012-12-20 2016-12-23 生物马特里卡公司 用於使pcr试剂稳定化的制剂和方法
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
EP3007556B1 (en) 2013-06-13 2020-05-20 Biomatrica, INC. Cell stabilization
MD4658B1 (ro) 2013-12-20 2019-11-30 Gilead Sciences Inc Inhibitori ai kinazei inductoare de apoptoză
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
US20150342943A1 (en) 2014-06-03 2015-12-03 Gilead Sciences, Inc. Methods of treating liver disease
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
SG11201700341PA (en) 2014-07-17 2017-02-27 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders
TW201618781A (zh) 2014-08-13 2016-06-01 吉李德科學股份有限公司 治療肺高血壓之方法
AU2015320792B2 (en) 2014-09-24 2018-08-30 Gilead Sciences, Inc. Methods of treating liver disease
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
JP6439050B2 (ja) 2014-12-23 2018-12-19 ギリアード サイエンシーズ， インコーポレイテッド Ａｓｋ１阻害剤を調製するプロセス
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2017100212A1 (en) 2015-12-08 2017-06-15 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
FR3050112B1 (fr) 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN110036005B (zh) * 2016-11-16 2022-09-27 广东东阳光药业有限公司 酰胺衍生物及其在药物中的应用
WO2018157856A1 (zh) 2017-03-03 2018-09-07 江苏豪森药业集团有限公司 酰胺类衍生物抑制剂及其制备方法和应用
PL3621615T3 (pl) 2017-05-12 2024-03-25 Enanta Pharmaceuticals, Inc. Inhibitory regulujące sygnał apoptozy kinazy 1 i sposoby ich stosowania
US10450301B2 (en) 2017-05-25 2019-10-22 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10246439B2 (en) 2017-05-25 2019-04-02 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10253018B2 (en) 2017-05-25 2019-04-09 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019034096A1 (en) * 2017-08-17 2019-02-21 Sunshine Lake Pharma Co., Ltd. FUSED BICYCLIC COMPOUNDS AND THEIR USES IN MEDICINE
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10370352B2 (en) 2017-09-07 2019-08-06 Eli Lilly And Company Cyclobutyl-imidazolidinone compounds
WO2019047094A1 (en) * 2017-09-07 2019-03-14 Eli Lilly And Company CYCLOBUTYL-IMIDAZOLIDINONE COMPOUNDS
JP2020533335A (ja) * 2017-09-08 2020-11-19 フロンセラ ユー．エス． ファーマシューティカルズ エルエルシー アポトーシスシグナル調節キナーゼ阻害剤およびその使用
CN111518080A (zh) * 2017-10-12 2020-08-11 深圳市塔吉瑞生物医药有限公司 一种1,2,4-三氮唑类化合物
WO2019099703A1 (en) * 2017-11-16 2019-05-23 Sidecar Therapeutics, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
CN111655678B (zh) * 2018-01-05 2023-08-22 广州市恒诺康医药科技有限公司 细胞凋亡信号调节激酶-1抑制剂及其应用
CN110294742B (zh) * 2018-03-21 2023-01-31 山东轩竹医药科技有限公司 并环类ask1抑制剂及其应用
EP4537902A3 (en) * 2018-04-12 2025-06-11 Terns, Inc. Tricyclic ask1 inhibitors
CN110407806B (zh) 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
US10683289B2 (en) 2018-05-02 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
JP7328254B2 (ja) 2018-05-02 2023-08-16 エナンタ ファーマシューティカルズ インコーポレイテッド アポトーシスシグナル調節キナーゼ１阻害剤を含むテトラゾール及びその使用方法
CA3109504A1 (en) * 2018-08-14 2020-02-20 Biogen Ma Inc. Ask1 inhibiting agents
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020198214A1 (en) 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN111018831B (zh) * 2019-11-21 2022-05-31 中国药科大学 细胞凋亡信号调节激酶抑制剂及其应用
WO2021127643A1 (en) * 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
WO2021252555A1 (en) * 2020-06-09 2021-12-16 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
TW202220967A (zh) * 2020-07-24 2022-06-01 美商伊尼製藥股份有限公司 噻吩hsd17b13抑制劑及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
CA1121825A (en) * 1978-04-11 1982-04-13 Franco Bolasco 2-(2-thenoylthio)-propionylglycine: method for its preparation and pharmaceutical formulations containing said compound
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW513418B (en) * 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
WO1998034946A1 (en) 1997-02-12 1998-08-13 Massachusetts Institute Of Technology Daxx, a novel fas-binding protein that activates jnk and apoptosis
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
AU782448B2 (en) 1999-03-19 2005-07-28 Aventis Pharmaceuticals Inc. Akt nucleic acids, polypeptides, and uses thereof
US20070237770A1 (en) 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
EP1661581A1 (en) 2003-07-28 2006-05-31 Osaka Industrial Promotion Organization Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same
US7078064B2 (en) * 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
EP1794137A4 (en) 2004-09-27 2009-12-02 Kosan Biosciences Inc SPECIFIC KINASE INHIBITORS
EP1677113A1 (en) 2004-12-29 2006-07-05 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Method for the identification of protein-protein interactions in disease related protein networks
JP2009524677A (ja) * 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物
US20070276050A1 (en) 2006-02-27 2007-11-29 Gilead Sciences, Inc. Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases
WO2008011560A2 (en) * 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
JPWO2008016131A1 (ja) * 2006-08-04 2009-12-24 武田薬品工業株式会社 縮合複素環化合物
EP2104734A2 (en) 2006-12-08 2009-09-30 Asuragen, INC. Mir-20 regulated genes and pathways as targets for therapeutic intervention
US8263595B2 (en) * 2007-08-31 2012-09-11 Merck Serono Sa Triazolopyridine compounds and their use as ask inhibitors
JP5432982B2 (ja) 2008-03-31 2014-03-05 武田薬品工業株式会社 アポトーシスシグナル調節キナーゼ１阻害剤
US8178555B2 (en) 2008-06-24 2012-05-15 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2010045470A2 (en) 2008-10-15 2010-04-22 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders
US20110294693A1 (en) 2008-11-17 2011-12-01 The George Washington University Compositions and Methods for Identifying Autism Spectrum Disorders
EP2411516A1 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
TWI625121B (zh) * 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US8802695B2 (en) 2010-02-03 2014-08-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2011097594A2 (en) 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
RU2018100142A (ru) 2010-03-24 2019-02-20 Амитек Терапетикс Солюшинс, Инк. Гетероциклические соединения, эффективные для ингибирования киназы
SI2588475T1 (sl) * 2010-07-02 2015-12-31 Gilead Sciences, Inc. Kinazni inhibitorji za regulacijo apoptoznega signala
CN103492590A (zh) 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 循环生物标志物
JP2014526032A (ja) 2011-06-07 2014-10-02 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 癌に対する循環バイオマーカー
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
MD4658B1 (ro) * 2013-12-20 2019-11-30 Gilead Sciences Inc Inhibitori ai kinazei inductoare de apoptoză

Also Published As

Publication number Publication date
MX2012015105A (es) 2013-05-28
AU2011272782B2 (en) 2014-11-27
HK1184781A1 (en) 2014-01-30
ES2543428T3 (es) 2015-08-19
EA023040B1 (ru) 2016-04-29
JP2013530240A (ja) 2013-07-25
IL223556A (en) 2016-08-31
US20130203819A1 (en) 2013-08-08
CN102985418A (zh) 2013-03-20
PL2588475T3 (pl) 2015-10-30
PT2588475E (pt) 2015-09-08
NZ604831A (en) 2014-12-24
IL247405A0 (en) 2016-11-30
EP2588475A1 (en) 2013-05-08
US20120004267A1 (en) 2012-01-05
CA2802743C (en) 2019-05-07
USRE48150E1 (en) 2020-08-11
WO2012003387A1 (en) 2012-01-05
US8927582B2 (en) 2015-01-06
EP2588475B1 (en) 2015-05-20
KR20130129890A (ko) 2013-11-29
BR112012033715A2 (pt) 2016-11-22
KR101759759B1 (ko) 2017-07-19
US8440665B2 (en) 2013-05-14
CN102985418B (zh) 2015-09-09
CA2802743A1 (en) 2012-01-05
EA201291273A1 (ru) 2013-06-28
AU2011272782A1 (en) 2013-01-10
SI2588475T1 (sl) 2015-12-31

Similar Documents

Publication Publication Date Title
JP5705314B2 (ja) アポトーシスシグナル調節キナーゼ阻害剤
JP5745721B2 (ja) アポトーシスシグナル調節キナーゼ阻害剤
CN104918936B (zh) 作为细胞凋亡信号调节激酶抑制剂的经取代的吡啶-2-甲酰胺化合物
TWI537266B (zh) 充當離子通道調節劑的稠合雜環化合物
TWI466873B (zh) 作為離子通道調節劑之稠合雜環化合物
US8952007B2 (en) Fused heterocyclic compounds as ion channel modulators
JP2017193592A (ja) アポトーシスシグナル調節キナーゼ阻害剤
US8389500B2 (en) Fused heterocyclic compounds as ion channel modulators
HK1184781B (en) Apoptosis signal-regulating kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150224

R150 Certificate of patent or registration of utility model

Ref document number: 5705314

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250